Deze website met internetadres http://www.pfizerpro.nl en alle hierop vermelde informatie is uitsluitend gericht op inwoners van Nederland.

Zoek

Menu

Close

Inloggen of registrerenUitloggenOnze geneesmiddelenZiektebeeldenOntdek meerOntdek meerEducatieMaterialenVideo'sPodcastOver PfizerOver PfizerNieuwsBlogsMedewerkers in beeldContactContactNeem gerust contact met ons opStel een vraagPfizer medische informatie

Onderaan de pagina kunt u bijwerkingen melden.

Home

Menu

Close

EfficacyEfficacy DataTrial DesignClinical RemissionEndoscopic ImprovementBio/JAKi Subgroups DataIsolated ProctitisSafetyAdverse eventsCardiac and ocular adverse eventsGetting StartedResourcesEventsMaterialsVideos
Biologic/JAKi Subgroups Data

ELEVATE UC 52

ELEVATE UC 12

Tab Number 3

Tab Number 4

Tab Number 5

VELSIPITY efficacy in biologic/JAKi subgroups
Patients on VELSIPITY achieved clinical remission in both the biologic/JAKi-naive and biologic/JAKi-exposed subgroups in ELEVATE UC 521,2
Advanced therapies include S1P receptor modulators, biologics, and JAK inhibitors.3Clinical remission was defined as a stool frequency (SF) subscore of 0 (or of 1 with a ≥1-point decrease from baseline), a rectal bleeding (RB) subscore of 0, and an endoscopy score (ES) ≤1 (excluding friability).1Analysis of outcomes by prior treatment was not powered for statistical significance.3,4 Clinical remission was controlled for multiplicity via parallel gatekeeping procedures that preserved the type I error rate at 5%.3
VELSIPITY efficacy in biologic/JAKi subgroups
Patients on VELSIPITY achieved clinical remission in both the biologic/JAKi-naive and biologic/JAKi-exposed subgroups in ELEVATE UC 121,2
Advanced therapies include S1P receptor modulators, biologics, and JAK inhibitors.3Clinical remission was defined as a stool frequency (SF) subscore of 0 (or of 1 with a ≥1-point decrease from baseline), a rectal bleeding (RB) subscore of 0, and an endoscopy score (ES) ≤1 (excluding friability).1Analysis of outcomes by prior treatment was not powered for statistical significance.3,4
Clinical remission was controlled for multiplicity via parallel gatekeeping procedures that preserved the type I error rate at 5%.3
References:VELSIPITY (etrasimod) Summary of Product Characteristics. Brussels, Belgium: Pfizer Europe; February 2024.Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies [published correction appears in Lancet. 2023;401(10381):1000]. Lancet. 2023;401(10383):1159-1171. Supplementary appendix available at: https://www.thelancet.com/cms/10.1016/S0140-6736(23)00061-2/attachment/cdbbc759-490f-4b2a-a3a2-93bc9918b29f/mmc1.pdf. Accessed December 18, 2023.Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies [published correction appears in Lancet. 2023;401(10381):1000]. Lancet. 2023;401(10383):1159-1171.Data on file. Pfizer Inc.
Isolated Proctitis

See how VELSIPITY is effective in calming the chaos of isolated proctitis.

SEE ISOLATED PROCTITIS Loading
PP-V1A-NLD-0012

Wilt u een bijwerking melden? Ga dan naar de 'Bijwerkingen melden' pagina en klik vervolgens op u van toepassing zijnde button.

PfizerPro AccountPfizerPro AccountU vindt informatie over geneesmiddelen, werkingsmechanismen, werkzame stoffen, doseringen en bijwerkingen die kunnen optreden. Zodat u nog beter in staat bent om uw patiënten te helpen.InloggenRegistrerenAccountUitloggen

De informatie die op deze website wordt aangeboden is uitsluitend bedoeld voor zorgverleners in Nederland. Bent u geen zorgverlener, maar patiënt of consument, ga dan naar www.pfizer.nl.

 

2025 Pfizer© Alle rechten voorbehouden.
 

PP-V1A-NLD-0012
U verlaat de website van Pfizer
Door op oké te klikken, verlaat u de website van Pfizer. De links naar websites buiten Pfizer worden u als service aangeboden. Pfizer heeft geen invloed op de inhoud van deze sites en is er niet voor verantwoordelijk.